CN109311959A - 肽类似物 - Google Patents
肽类似物 Download PDFInfo
- Publication number
- CN109311959A CN109311959A CN201780015231.1A CN201780015231A CN109311959A CN 109311959 A CN109311959 A CN 109311959A CN 201780015231 A CN201780015231 A CN 201780015231A CN 109311959 A CN109311959 A CN 109311959A
- Authority
- CN
- China
- Prior art keywords
- group
- acy
- acylated
- residues
- empty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310002994.XA CN116063580A (zh) | 2016-01-04 | 2017-01-04 | 肽类似物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662274638P | 2016-01-04 | 2016-01-04 | |
| US62/274,638 | 2016-01-04 | ||
| PCT/US2017/012171 WO2017120220A1 (en) | 2016-01-04 | 2017-01-04 | Peptide analogs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310002994.XA Division CN116063580A (zh) | 2016-01-04 | 2017-01-04 | 肽类似物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109311959A true CN109311959A (zh) | 2019-02-05 |
Family
ID=59274070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780015231.1A Pending CN109311959A (zh) | 2016-01-04 | 2017-01-04 | 肽类似物 |
| CN202310002994.XA Pending CN116063580A (zh) | 2016-01-04 | 2017-01-04 | 肽类似物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310002994.XA Pending CN116063580A (zh) | 2016-01-04 | 2017-01-04 | 肽类似物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11034745B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3400237A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7360794B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109311959A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201734035A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017120220A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200353088A1 (en) * | 2017-11-06 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof |
| US20210332083A1 (en) * | 2018-12-12 | 2021-10-28 | The Regents Of The University Of California | Netrin-1 Compounds and Compositions Thereof for Treating Pulmonary Hypertension |
| CN114686427B (zh) * | 2022-05-23 | 2022-07-29 | 中国人民解放军总医院第一医学中心 | 一种脾脏调节型b淋巴细胞及其制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080020978A1 (en) * | 2005-10-21 | 2008-01-24 | Gegg Colin V Jr | CGRP peptide antagonists and conjugates |
| US20130281374A1 (en) * | 2006-08-17 | 2013-10-24 | Astrazeneca Pharmaceuticals Lp | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
| CN103458916A (zh) * | 2011-04-07 | 2013-12-18 | 小利兰·斯坦福大学托管委员会 | 长效肽类似物 |
| CN104271596A (zh) * | 2012-01-26 | 2015-01-07 | 克里斯托弗·J·索尔斯 | 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| AU5366296A (en) | 1995-03-22 | 1996-10-08 | Trustees Of Boston University | Methods for the detection of paracoccidioides |
| US6440421B1 (en) | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
| IL118003A0 (en) | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
| US6268474B1 (en) | 1998-04-30 | 2001-07-31 | Creighton University | Peptide antagonists of CGRP-receptor superfamily and methods of use |
| US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
| US6965013B2 (en) | 2002-11-26 | 2005-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
| US20080026995A1 (en) | 2003-07-25 | 2008-01-31 | Ac Immune Sa | Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| RU2385878C2 (ru) | 2004-02-11 | 2010-04-10 | Амилин Фармасьютикалз, Инк. | Пептид, обладающий свойствами амилина (варианты), и его применение (варианты) |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| ZA200700359B (en) | 2004-07-21 | 2008-12-31 | Ambrx Inc | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| CA2580991A1 (en) | 2004-10-08 | 2006-04-20 | Amylin Pharmaceuticals, Inc. | Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them |
| TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
| CA2597649A1 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| MX2008002028A (es) | 2005-08-11 | 2008-03-27 | Amylin Pharmaceuticals Inc | Polipeptidos hibridos con propiedades de seleccion. |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| WO2008022716A2 (en) | 2006-08-22 | 2008-02-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening method for gpcr ligands |
| KR20090060294A (ko) | 2006-09-08 | 2009-06-11 | 암브룩스, 인코포레이티드 | 변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도 |
| US7956035B2 (en) | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| UA99914C2 (ru) | 2007-05-15 | 2012-10-25 | Оцука Фармас'Ютікел Ко., Лтд. | Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US20130011382A1 (en) * | 2010-01-08 | 2013-01-10 | Profibrix Bv | Fibrinogen Preparations Enriched In Fibrinogen With An Extended Alpha Chain |
| US9543468B2 (en) * | 2010-10-12 | 2017-01-10 | Alliance For Sustainable Energy, Llc | High bandgap III-V alloys for high efficiency optoelectronics |
| EP3416676B1 (en) | 2016-02-09 | 2021-12-08 | Adepthera LLC | Dosing and use of long-acting clr/ramp agonists |
-
2017
- 2017-01-04 US US16/066,609 patent/US11034745B2/en active Active
- 2017-01-04 CN CN201780015231.1A patent/CN109311959A/zh active Pending
- 2017-01-04 TW TW106100180A patent/TW201734035A/zh unknown
- 2017-01-04 WO PCT/US2017/012171 patent/WO2017120220A1/en not_active Ceased
- 2017-01-04 JP JP2018553861A patent/JP7360794B2/ja active Active
- 2017-01-04 CN CN202310002994.XA patent/CN116063580A/zh active Pending
- 2017-01-04 EP EP17736247.2A patent/EP3400237A4/en active Pending
-
2021
- 2021-05-10 US US17/316,153 patent/US20220340633A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080020978A1 (en) * | 2005-10-21 | 2008-01-24 | Gegg Colin V Jr | CGRP peptide antagonists and conjugates |
| US20130281374A1 (en) * | 2006-08-17 | 2013-10-24 | Astrazeneca Pharmaceuticals Lp | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
| CN103458916A (zh) * | 2011-04-07 | 2013-12-18 | 小利兰·斯坦福大学托管委员会 | 长效肽类似物 |
| CN104271596A (zh) * | 2012-01-26 | 2015-01-07 | 克里斯托弗·J·索尔斯 | 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途 |
Non-Patent Citations (1)
| Title |
|---|
| SAMUEL D ROBINSON ET AL.: "Novel peptide antagonists of adrenomedullin and calcitonin gene-related peptide receptors: identification, pharmacological characterization, and interactions with position 74 in receptor activity-modifying protein 1/3", 《J PHARMACOL EXP THER.》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US11034745B2 (en) | 2021-06-15 |
| US20190010203A1 (en) | 2019-01-10 |
| JP7360794B2 (ja) | 2023-10-13 |
| CN116063580A (zh) | 2023-05-05 |
| US20220340633A1 (en) | 2022-10-27 |
| WO2017120220A1 (en) | 2017-07-13 |
| EP3400237A1 (en) | 2018-11-14 |
| JP2019504119A (ja) | 2019-02-14 |
| TW201734035A (zh) | 2017-10-01 |
| EP3400237A4 (en) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12110318B2 (en) | Peptide analogs | |
| KR102440323B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| TWI666220B (zh) | 醯化升糖素類似物 | |
| JP4949844B2 (ja) | エリスロポエチン受容体に結合する新規ペプチド | |
| JP6334537B2 (ja) | グルカゴン類似体 | |
| JP2019112437A (ja) | グルカゴン類似体 | |
| JP2020045362A (ja) | グルカゴン−glp−1−gipトリプルアゴニスト化合物 | |
| CN102397558B (zh) | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 | |
| ES2988026T3 (es) | Agonistas del receptor CRF2 y su uso en terapia | |
| TWI763972B (zh) | 經修飾之脂質化鬆弛素b鏈胜肽及其醫療用途 | |
| EP3570875B1 (en) | Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use | |
| JP2000516579A (ja) | 腸栄養性glp―2ペプチドのアンタゴニスト | |
| SG186764A1 (en) | Glucagon analogues | |
| JP2007204491A (ja) | グルカゴン様ペプチド−2アナログ | |
| CN106913865A (zh) | 使用白细胞介素‑10治疗疾病和病症的方法 | |
| CA2560174A1 (en) | Y4 selective receptor agonists for therapeutic interventions | |
| JP2021515759A (ja) | コンプスタチン類似体及びその医療用途 | |
| WO2023165476A1 (zh) | 针对sort1的多肽化合物及其药物偶联物 | |
| US20220340633A1 (en) | Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones | |
| CN114641303A (zh) | Npy2受体激动剂 | |
| CN107001440A (zh) | 稳定化的肾上腺髓质素衍生物及其用途 | |
| CN109310779A (zh) | 缀合的c1酯酶抑制剂及其用途 | |
| TW202438512A (zh) | Glp1/gip/npy2受體之三重促效劑 | |
| Niida et al. | Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives | |
| JP6005732B2 (ja) | 非ペプチド性重合体−インスリン多量体及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |